BIIB vs LLY
Biogen vs Eli Lilly and Company — AI-powered side-by-side comparison
VS
LLY
Eli Lilly and Company
68
Buy
| Metric | BIIB | LLY |
|---|
| AI Score |
70
|
68
|
| Price |
$209.75
|
$1,180.33
|
| P/E Ratio |
36.94×
|
39.54×
|
| ROE |
7.1%
|
77.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
84.0%
|
| Debt / Equity |
0.44×
|
1.62×
|
| Dividend Yield |
0.0%
|
0.6%
|
| RSI (14) |
60.9
|
57.1
|
| Beta |
0.162
|
0.506
|
| Expected Upside |
+4.3%
|
+5.8%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus LLY.
BIIB leads by 2 points.
BIIB scores 70/100 (Buy) versus LLY at 68/100 (Buy).
BIIB Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth